Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS)

Historical Holders from Q4 2014 to Q3 2025

Symbol
CHRS on Nasdaq
Type / Class
Equity / Common Stock, $0.0001 par value per share
Shares outstanding
117M
All holders as of 30 Sep 2025
Q3 2025
Total 13F shares, excl. options
51.6M
Holdings value
$84.5M
% of all portfolios
0%
Grand Portfolio weight change
0%
Number of holders
110
Number of buys
54
Number of sells
-47
Average Value change %
0%
Average buys %
+0%
Average sells %
0%
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors

Significant Owners of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS)

Filer Ownership Change % Holdings Value Net Change Nb Shares Change % Reporting Name Report Period
BlackRock, Inc. 6.6% -30% $7.62M -$3.46M 7.62M -31.2% BlackRock, Inc. 31 Mar 2025
Bering Partners II, L.P. 6.5% $12.5M 7.6M Evgeny Zaytsev ("Zaytsev") 05 Sep 2025
SATTERFIELD THOMAS A JR 5.2% $6.01M 6.01M Thomas A. Satterfield, Jr. 14 Apr 2025
Rubric Capital Management LP 4.56% $5.26M 5.26M Rubric Capital Management LP 31 Dec 2024

Institutional Holders of Coherus Oncology, Inc. - Common Stock, $0.0001 par value per share (CHRS)

Period Reported Shares, Excl. Options Value, Excl. Options Change Price Investors
2025 Q3 51.6M $84.5M -$2.98M $1.64 110
2025 Q2 55.4M $40.4M -$4.93M $0.73 109
2025 Q1 62.1M $50.1M -$6.46M $0.81 114
2024 Q4 65.6M $90.5M -$12.5M $1.38 121
2024 Q3 76.9M $79.9M -$12M $1.04 127
2024 Q2 82.6M $143M -$603K $1.73 132
2024 Q1 82.5M $197M -$5.91M $2.39 134
2023 Q4 81.5M $271M -$37.4M $3.33 153
2023 Q3 93M $348M +$14.5M $3.74 168
2023 Q2 86.7M $370M +$30.6M $4.27 159
2023 Q1 78.4M $536M -$2.03M $6.84 163
2022 Q4 78.7M $623M +$2.38M $7.92 160
2022 Q3 77.7M $746M -$14.9M $9.61 168
2022 Q2 78.9M $572M +$12.4M $7.24 171
2022 Q1 75.9M $980M -$19.1M $12.91 172
2021 Q4 76.7M $1.23B +$9.15M $15.96 190
2021 Q3 76.1M $1.22B -$23.9M $16.07 182
2021 Q2 77.9M $1.08B -$38.4M $13.83 184
2021 Q1 80.3M $1.17B -$126M $14.61 201
2020 Q4 86.8M $1.51B +$7.07M $17.38 191
2020 Q3 88M $1.62B -$17.6M $18.34 200
2020 Q2 86.7M $1.55B +$229M $17.86 187
2020 Q1 74.7M $1.21B +$27.8M $16.22 185
2019 Q4 72.7M $1.31B +$50.5M $18.00 184
2019 Q3 69.4M $1.41B +$54.9M $20.26 165
2019 Q2 66.8M $1.47B +$29.4M $22.10 145
2019 Q1 68.7M $938M +$43.9M $13.64 114
2018 Q4 65.7M $595M -$13.9M $9.05 107
2018 Q3 63.6M $1.05B +$28.5M $16.50 106
2018 Q2 62M $867M +$96.2M $14.00 112
2018 Q1 55.3M $611M +$32.9M $11.05 102
2017 Q4 49.5M $435M +$17.2M $8.80 92
2017 Q3 46.9M $627M +$87.2M $13.35 90
2017 Q2 40.1M $576M +$26.1M $14.35 105
2017 Q1 37.5M $793M +$211M $21.15 109
2016 Q4 29.9M $842M +$50.8M $28.15 122
2016 Q3 28.1M $754M +$78.4M $26.78 116
2016 Q2 25.3M $428M +$112M $16.89 86
2016 Q1 18.2M $387M +$29.1M $21.23 74
2015 Q4 16.7M $384M +$8.94M $22.96 76
2015 Q3 16.1M $322M +$17.3M $20.04 76
2015 Q2 15M $434M +$223M $28.90 73
2015 Q1 7.27M $222M -$28.1M $30.58 49
2014 Q4 9.85M $158M +$158M $16.32 37